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OBJECTIVES: To estimate the cost-effectiveness of pregabalin
and other add-on antiepileptic drug therapies in patients with
refractory partial epilepsy [RPE] in Argentina METHODS:
Using simulation modeling techniques, we estimated clinical out-
comes and costs for a hypothetical cohort of 1000 patients with
RPE alternatively assumed to receive pregabalin (300 and 
600 mg/d), lamotrigine (300 and 500 mg/d), oxcarbazepine
(1200 and 2400 mg/d), topiramate (200 and 400 mg/d), and no
add-on therapy. Outcomes of interest were examined assuming
no therapy discontinuation and included the expected mean
number of days free of seizures (“seizure-free days” [SFD]) and
the costs of add-on antiepileptic medication over one year for
each therapy. Parameter estimates were based on efﬁcacy data
from randomized controlled trials of these agents and costs of
medications (in Argentine Pesos [ARS]) from local sources. Cost-
effectiveness was calculated as the incremental cost (vs no add-
on therapy) per additional SFD. RESULTS: The incremental cost
of pregabalin (vs no add-on therapy) per additional SFD was
(mean (95% CI), ARS) 117 (91,152) for pregabalin 300 mg/d,
194 (166, 228) for lamotrigine (300 mg/d), 120 (100,150) for
oxcarbazepine (2400 mg/d), and 235 (99, 1071) for topiramate
(400 mg/d). When higher dosages were examined values were
157 (132, 181) for pregabalin 600 mg/d, 306 (271, 356) for lam-
otrigine (500 mg/d), 176 (145, 212) for oxcarbazepine (2400
mg/d), and 196 (142, 269) for topiramate (400 mg/d). CON-
CLUSION: The estimated cost-effectiveness of add-on antie-
pileptic therapy vs no add-on therapy for patients with RPE in
Argentina is favorable for pregabalin (117–157 ARS per addi-
tional SFD) followed by OXC (120–176 ARS per additional
SFD).
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OBJECTIVES: Natalizumab is a new disease-modifying therapy
(DMT) for the treatment of relapsing multiple sclerosis (MS). A
model was designed to determine the relative cost-effectiveness
of natalizumab compared with the other four currently available
disease-modifying therapies (intramuscular [IM] interferon beta
[IFNβ]-1a, IFNβ-1b, glatiramer acetate [GA], and subcutaneous
[SC] IFNβ-1a) for the treatment of relapsing MS in the United
States. METHODS: Analyses were conducted from a managed
care perspective with a time horizon of 2 years (ﬁrst 2 years after
initiation of therapy). Model inputs were drug acquisition costs,
costs of drug administration and monitoring, costs of treating
relapses, and anticipated reduction in relapse rates. Outcomes
included total 2-year costs per patient and costs per relapse
avoided for each therapy. Number of relapses avoided was cal-
culated as the weighted average number of relapses for placebo-
treated patients (1.90) multiplied by the anticipated relapse rate
reduction for each therapy (natalizumab, 67%; IM IFNβ-1a,
32%; IFNβ-1b, 34%; GA, 29%; and SC IFNβ-1a, 32%). Cost
per relapse avoided was calculated as the total 2-year cost of
therapy divided by the number of relapses avoided over 2 years.
RESULTS: The overall 2-year cost of therapy per patient was
$67,037 for natalizumab, $42,311 for IM IFNβ-1a, $44,680 for
IFNβ-1b, $44,300 for GA, and $46,373 for SC IFNβ-1a. The cost
per relapse avoided was lowest for natalizumab at $52,605 
followed by $69,091 for IFNβ-1b, $69,517 for IM IFNβ-1a,
$76,191 for SC IFNβ-1a, and $80,314 for GA. Model inputs with
the most inﬂuence on cost per relapse avoided for natalizumab
were weighted average number of relapses prior to treatment and
anticipated relative reduction in relapse rate. CONCLUSION:
Although the drug acquisition cost of natalizumab was higher
than that of the other DMTs, it was the most cost-effective therapy
as measured by total cost per relapse avoided.
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OBJECTIVES: The objective of this study was to estimate the
direct and indirect costs of treated and untreated insomnia in an
employed population. METHODS: The Medstat MarketScan®
Database was used for this study. Patients were included if they
had a primary diagnosis of insomnia and/or received a new pre-
scription for a non-benzodiazepine hypnotic medication between
July 1, 1999 and June 31, 2003. Total health care costs, plus
costs due to absenteeism, were calculated for the insomnia
cohort (n = 5605), and for the propensity score matched non-
insomnia cohort (total n = 55,580), during 6-month pre-index
and post-index periods. Change in total costs were compared
using an ordinary least square model for insomnia patients who
were treated versus not initially treated with a prescription hyp-
notic within 14 days of an insomnia diagnosis. RESULTS: Prior
to matching, the insomnia cohort was slightly younger (40 vs.
42 years), more likely to be female (44% vs 31%), and had sig-
niﬁcantly more medical and psychiatric comorbidity than the
non-insomnia cohort (Charlson Comorbidity Index score 0.32
vs. 0.11; P < 0.01). After using propensity score matching and
second stage regressions, the difference in average total expen-
ditures in the 6-month post-index period between the cohort of
insomnia patients (n = 5584) and matched non-insomnia con-
trols—the burden of insomnia—was $2738 (p < 0.001). Health
care utilization contributed to 84% of total insomnia-related
costs, while absenteeism contributed 16%. Six-month costs for
prescription hypnotics averaged less than $100 per patient. Both
the treated and initially untreated insomnia patients experienced
an increase in total costs; however, the increase for treated
insomnia patients was $788 less than for the initially untreated
insomnia patients. CONCLUSION: Insomnia has a signiﬁcant
impact on direct health care cost, and on costs related to absen-
teeism. Insomnia treatment appears to be cost-effective relative
to non-treatment, or delayed treatment.
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OBJECTIVES: To estimate expected clinical and economic 
consequences of induced changes in body weight associated 
